Creso Pharma Limited (ASX:CPH) has made the maiden delivery of the first orders of medicinal 10% CBD Oil to JC Logistics Ltd t/a MedLeaf Therapeutics in New Zealand.
Dr Miri Halperin Wernli, Creso Pharma’s CEO and co-founder, said he delivery marks the partnerships’ second product introduction to New Zealand in 2019.
“The evolving local regulatory situation and our close partnership with MedLeaf is helping us deliver on our mission to bring life-improving products to patients in New Zealand,” Dr Wernli said.
We’re delighted to announce this further expansion of our business and look forward to further new product introductions in the near future”. MedLeaf CEO and founder, Courtney Letica, said her company’s ultimate aim is to develop a world class, New Zealand-based cannabis business with leading research and development, cultivation, extraction and product development capabilities.
“After three years of patient advocacy, MedLeaf Therapeutics is proud to leverage this great relationship with Creso Pharma to bring greater choice to New Zealanders.
“With the environmentally sustainable, outdoor sun-grown crops from PharmaCielo and great product development of Creso Pharma, this partnership will see an opportunity for New Zealanders to gain access to affordable, highest quality, broad spectrum, GMP products”.
Ms Leticia said MedLeaf and Creso worked closely together to identify the most suitable medicinal CBD Oil product to introduce to New Zealand to meet patient needs.
“‘MedLeaf CBD Oil contains CBD from full spectrum hemp plant extracts, refined to 98% purity. It contains 100mg of CBD per ml and comes in an easy to use, 25ml dispensing bottle. MedLeaf and Creso will continue to introduce further products which meet with demand from physicians and patients.”
